BMBernhard Morell

Bernhard Morell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bernhard Morell has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Upfront unroofing of subepithelial lesions using cold snare in the upper and lower gastrointestinal tract: a retrospective study from Switzerland

    by Bernhard Morell, Jasmina El Hadad-Burla, Frans Olivier The, Fabian Reinisch, Christoph Gubler, Fritz Ruprecht Murray

    Background/Aims: Subepithelial lesions (SELs) are frequently encountered in the upper and lower gastrointestinal (GI) tracts during routine endoscopy. As a significant proportion of SELs harbor malignant potential, a definitive diagnosis with tissue sampling should be sought in most patients. However, small SELs (<20 mm) represent a clinical challenge because endoscopic ultrasound-guided tissue acquisition may not be as efficient under these circumstances. Furthermore, mucosal incision biopsies require equipment that is not universally available.Methods: We retrospectively investigated the diagnostic yield and safety of cold snare unroofing in an observational cohort.Results: A total of 71 SELs (41 in the upper GI tract and 30 in the lower GI tract) with a median size of 10 mm (range, 3–60 mm) were included. Unroofing resulted in a histologic diagnosis in 85% (n=60) of cases, with no further diagnostic procedures or surveillance required in 88.3% (n=53/60). The final diagnoses consisted of 10 different etiologies, including three GI stromal tumors, one neuroendocrine tumor, and 44 lipomas. No significant complications, such as bleeding or perforation, were observed.Conclusions: Cold snare unroofing represents an efficient and easy method for characterizing small SELs in the upper and lower GI tracts, offering a valuable alternative to mucosal incision-assisted biopsy (MIAB) and endoscopic ultrasound with fine-needle biopsy.

  • Patient preferences regarding treatment options in eosinophilic oesophagitis: swallowed topical steroids overwhelmingly preferred—however, fear of side effects needs to be addressed

    by Bernhard Kaspar Morell, Philipp Schreiner, Andrea Kreienbühl, Ahmed Madisch, Ulrike von Arnim, Fritz Ruprecht Murray, Luc Biedermann

    Objective: The approval of budesonide orodispersible tablets and dupilumab has introduced new therapeutic options for the treatment of eosinophilic oesophagitis (EoE). However, there is a shortage of data on perspectives of the affected patients regarding therapeutic interventions. We aimed to assess the beliefs, restrictions and preferences of patients with EoE with respect to medical and dietary treatment options. Design/method: We conducted a web-based survey consisting of 34 questions addressing treatment preferences, including currently available and potentially emerging options, using SurveyMonkey among patients with confirmed diagnosis of EoE in Switzerland, Austria and Germany. Results: 150 patients (64% male; 70.7% with concomitant atopic diseases; 44% previously dilated; 22% with ≥3 sessions) responded. With regard to the routes of administration, one to two times daily swallowed topical corticosteroid (STC) was ranked the highest (89.3% generally preferred STC, and 52.7% preferred STC as single most preferred route within the scenario, including every potentially imaginable route of administration and assuming all options would be equally effective), followed by subcutaneous administration every 4 weeks (62.7%, 22%), peroral systemic steroids (46.7%, 18.7%) and weekly subcutaneous administration (38.7%, 0%). Although one-third did not have reservations against long-term medical therapy, 42% were sceptical about long-term treatment and 65% were afraid of adverse events. Patients with fear of drug-related side events were significantly younger (p=0.001), less often dilated (ever) (p=0.03) and had more often experienced adverse events of any prior therapy (p=0.03). Conclusion: Patients with EoE prefer topical agents over other available routes of administration. Patient education is crucial to address concerns regarding long-term treatment.

  • Open Access

    Wide discrepancy between best practice recommendations and real-life management of suspected eosinophilic esophagitis-associated food bolus impaction

    by Yangzom Siegfried, Jagoda Pokryszka, Petr Hruz, Simon Buetikofer, Bernhard Morell, Fritz R Murray, Ekaterina Safroneeva, Andrea Kreienbuehl, Thomas Greuter, Alex Straumann, et al.

    SUMMARY: Esophageal food impaction (EFI) is the leading complication in patients with undiagnosed eosinophilic esophagitis (EoE). Limited data exists on pre-hospital care, in-hospital management, and post-hospital follow-up in suspected EoE-associated EFI. This study aims to assess deviations between real-life management and guideline-based recommendations in suspected EoE-associated EFI. This retrospective multicenter study analyzed data from four major Swiss gastroenterology units on patients with EoE-associated EFI. Patients with GERD-related strictures or esophageal cancer were excluded. Data on demographics, emergency department (ED), endoscopy management, and follow-up were obtained from electronic health records. Associations between clinical factors and odds of biopsy were analyzed using logistic regression. Between January 2015 and December 2020, 198 EFI cases (median age 51 years, 29.8% female, 28% with previous EFI) were recorded. Patient delay—the time between symptom onset and ED admission—was ~ 270 minutes. Nearly all patients (94%) required endoscopic bolus removal. The median time from ED presentation to endoscopy was ~150 minutes. Esophageal biopsies were taken in just over half of the individuals (n = 97, 52%), leading to a new EoE diagnosis in 71 (68.9% of those biopsied). Biopsy odds decreased significantly with older age (OR 0.96; 95% CI 0.94–0.98, P < 0.05) and known EoE (OR 0.26; 95% 0.09–0.69, P < 0.05). Although EoE is a leading cause of EFI, too few patients with a high baseline probability of EoE undergo biopsy in the emergency setting. Among those biopsied, the majority received a new EoE diagnosis, highlighting the importance of histological assessment.


  • Loss of Response to Off-Label Swallowed Topical Corticosteroids in Eosinophilic Esophagitis Can be Overcome by a Switch to an Esophageal-Targeted Budesonide Formulation

    by Fritz R. Murray, Jean-Benoit Rossel, Ekaterina Safroneeva, Catherine Saner, Bernhard Morell, Andrea Kreienbuehl, Thomas Greuter, Alex Straumann, Luc Biedermann, Alain Schoepfer, et al.

    INTRODUCTION: Swallowed topical corticosteroids (STCs) are effective in treating patients with eosinophilic esophagitis. However, real-world data about loss of response to STC are limited and whether patients with off-label STC (olSTC) failure may achieve histologic remission after a switch to budesonide orodispersible tablets (BOT) is unknown. METHODS: We analyzed prospectively collected data between 2015 and 2023 from the Swiss Eosinophilic Esophagitis Cohort Study and compared patients with prior histologic olSTC-failure (≥15 eosinophils per high-power field), histologic remission after olSTC (P = 0.002), off-label STC adherence P = 0.03), and age P = 0.004) were independently associated with histologic nonresponse to olSTC. Histologic or combined remission to BOT was not different in patients with prior olSTC response (n = 44) compared to patients nonresponded to olSTC (n = 66) (77.3% vs 62.1%, P = 0.095 and 61.4% vs 42.4%, P = 0.052). DISCUSSION: Most patients nonresponding to olSTC are not true corticosteroid-refractory but respond to an esophageal-targeted budesonide formulation. Age below 30 years, longer treatment duration and low adherence are associated with olSTC-failure.


    • 1 November 2024
      • Vol. 113  (10) , 283-288

    [A Somehow Different Cause of an Upper Gastrointestinal Bleeding].

    by Bernhard Morell, Stephan Ullrich, Stefan Gutknecht, Pascal Weibel, Jörg Wydler, Christoph Gubler

    We report a case of an 89-year-old patient, who presented with melena and physical degradation at the emergency department. As cause for his symptoms, we found an upper GI-bleeding from a metastasis of a follicular thyroid carcinoma, for which the patient was surgically treated in the year 1996.

  • Open Access

    Long-term surveillance of gastric varices after cyanoacrylate injection in patients with non-cirrhotic portal hypertension: is it worth the effort?

    by Bernhard Morell, Fritz Ruprecht Murray, Christoph Gubler, Christoph Schlag, Andreas E. Kremer, Ansgar Deibel

    Long-term surveillance of gastric varices after cyanoacrylate injection in patients with non-cirrhotic portal hypertension: is it worth the effort?


  • Permanent Tunneled Drainage of Ascites in Palliative Patients: Timing Needs Evaluation

    by Fritz Ruprecht Murray, Florian Gnehm, Valeria Schindler, Bernhard Morell, Christoph Gubler, Eva-Maria Kretschmer, Simon Bütikofer

    Background: Treatment of refractory ascites remains challenging. We evaluated the safety and efficacy of permanent tunneled peritoneal catheters (PTPC) in this condition. Methods: We retrospectively analyzed consecutive patients in palliative situations in a tertiary referral center. Safety parameters, symptom relief, and survival were assessed. Results: Seventy patients were included from February 2012 to January 2021. Ninety percent had ascites due to malignancy, 10% due to end-stage liver disease. The technical procedure was successful in all cases; no deaths occurred. Procedure-related infections were rare and only observed in patients without peri-interventional antibiotics. Most patients experienced symptom relief (76%) and were satisfied with the device (83%). Survival after PTPC was relatively short (median 19 days). Discussion: PTPC is a safe option for refractory ascites in palliative settings with symptom relief in the majority of patients and should be considered early after onset of ascites. Periprocedural antibiotic prophylaxis may be considered to avoid procedure-related infections.


  • Clinical parameters associated with gastric portal hypertensive polyps

    by Florian Freimut Hildenbrand, Chantal Wohlwend, Stefanie von Felten, Ann-Katrin Rodewald, Fritz Ruprecht Murray, Frans Olivier The, Simon Bütikofer, Christoph Gubler, Bernhard Morell

    Portal hypertensive polyps (PHPs) are incompletely characterized lesions that can be found in the distal stomach of patients with portal hypertension. We aimed to delineate clinical factors associa...


  • Open Access

    Synonymous mutation in adenosine triphosphatase copper‐transporting beta causes enhanced exon skipping in Wilson disease

    by Marlene Panzer, André Viveiros, Benedikt Schaefer, Nadja Baumgartner, Klaus Seppi, Atbin Djamshidian, Theodor Todorov, William J. H. Griffiths, Eckart Schott, Markus Schuelke, et al.

    Wilson disease (WD) is caused by biallelic pathogenic variants in adenosine triphosphatase copper‐transporting beta (ATP7B); however, genetic testing identifies only one or no pathogenic ATP7B variant in a number of patients with WD. Synonymous single‐nucleotide sequence variants have been recognized as pathogenic in individual families. The aim of the present study was to evaluate the prevalence and disease mechanism of the synonymous variant c.2292C>T (p.Phe764=) in WD. A cohort of 280 patients with WD heterozygous for a single ATP7B variant was investigated for the presence of c.2292C>T (p.Phe764=). In this cohort of otherwise genetically unexplained WD, the allele frequency of c.2292C>T (p.Phe764=) was 2.5% (14 of 560) compared to 7.1 × 10−6 in the general population (2 of 280,964 in the Genome Aggregation Database; p < 10−5; Fisher exact test). In an independent United Kingdom (UK) cohort, 2 patients with WD homozygous for p.Phe764= were identified. RNA analysis of ATP7B transcripts from patients homozygous or heterozygous for c.2292C>T and control fibroblasts showed that this variant caused high expression of an ATP7B transcript variant lacking exon 8. Conclusion: The synonymous ATP7B variant c.2292C>T (p.Phe764=) causes abnormal messenger RNA processing of ATP7B transcripts and is associated with WD in compound heterozygotes and homozygotes.